

Oncology Strategy and ASCO R&D event

We are just getting started

June 2, 2020



Forward looking statements

This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. Any material effect of COVID-19 on any of the foregoing could also adversely impact us. This situation is changing rapidly and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2019. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Agenda

Introduction	Paul Hudson	Chief Executive Officer		
Sanofi in Oncology	John Reed	Executive Vice President, Global Head of Research & Development		
Sarclisa®	Dietmar Berger	Senior Vice President, Global Head of Development, Chief Medical Officer		
Libtayo®	Alexander Zehnder	Global Franchise Head, Oncology		
Anti-CEACAM5 '701	Peter Adamson	Global Oncology Development Head		
SERD '859	Peter Adamson	Global Oncology Development Head		
Conclusion	John Reed	Executive Vice President, Global Head of Research & Development		
Q&A session				



Introduction

Paul Hudson

Chief Executive Officer



Our ambition in Oncology



Transform strong science into commercial leadership



Focus on 4 core areas with ambition to shape 4 anchor assets into blockbusters



Develop novel combinations to improve patients' outcomes



Position Sanofi as partner of choice in selected areas based on best-in-class backbones and leading platforms to generate first-in-class medicines

Ambition to shape 4 anchor assets into blockbusters

	Ambition	Current status	Blockbuster potential
Sarclisa®(1)	Best-in-class profile in multiple myeloma	Approved with Pd for RRMM ⁽³⁾	Positive pivotal data with Kd in 2L+ RMM P3 (IKEMA) P3 in 1L Ti/Te MM ongoing SMM to be initiated ⁽⁴⁾
Libtayo ^{®(2)}	Serving larger patient populations with competitive profile	Approved in metastatic/locally advanced CSCC	Positive pivotal data in in 1L NSCLC Positive pivotal data in 2L BCC Adjuvant CSCC P3 ongoing Backbone for novel combinations
Anti-CEACAM5 '701 ^(1,5)	First-in-class CEACAM5-targeting ADC for lung cancer	PoC data in CEACAM5+ 2L nsq NSCLC (single agent)	Pivotal P3 (fast-to-market) 2L CEACAM5+ NSCLC ongoing, PoC in earlier NSCLC lines and further CEACAM5+ tumors initiating
SERD '859(1,5) Priority asset	Best-in-class endocrine backbone for HR+ breast cancer	PoC data in 3L+ HR+ BC (single agent)	Pivotal P2b (fast-to-market) in 2L+ HR+ BC PoC combo and studies in earlier lines ongoing

MM: multiple myeloma: RRMM: Relapsed/refractory multiple myeloma; TI: Transplant ineligible; Te: Transplant eligible; HR+: Hormone Receptor positive; CSCC: Cutaneous Squamous Cell Carcinoma: BCC: Basal Cell Carcinoma; NSCLC: Non-Small Cell Lung Cancer; SMM: Smoldering multiple myeloma; ADC: Antibody Drug Conjugate; BC: breast cancer; nsg: non-squamous; PoC: Proof of Concept, clinical and commercial evidence to initiate pivotal study

SANOFI 🎝

(1) Wholly owned assets (2) Libtayo® in collaboration with Regeneron - Sales are consolidated by Regeneron in the U.S. (3) and ≥2 prior therapies, including lenalidomide and a proteasome inhibitor. Approved in the U.S., EU, Canada, Australia and Switzerland, indication in certain non-U.S. countries also includes disease progression on last therapy (4) These uses of 6 isatuximab are investigational and have not been evaluated by any regulatory authority. (5) Anti-CEACAM5 '701 and SERD '859 not approved by the regulators

Momentum is building in Sanofi Oncology

May 5, 2020:

Libtayo[®] BCC

Libtayo® (cemiplimab) shows clinically meaningful and

Objective responses seen in 29% of patients with localizationand

In a continuinary analysis, chieving responses easy in 21% of patients

An estimated RS% of natients who responded to Libbavo maintainer

and Tarrytown, NY - May 5, 2020 - Topline data for a pivotal single-arm open

I trial for Sanofi and Regeneron's PD-1 inhibitor Libtayo® (cemiplimab) in patients with

ced basal cell carcinoma (BCC) who had progressed on or were intolerant to prior

eto gabin ver initialio (HH) therapy were announced today. Libitayo demonstrated alay meaningful and durable responses in this group of patients for whom there are no aved treatments. Sanofi and Regeneron plan regulatory submissions in 2020.

is a skin cancer and is the most common cancer worldwide, with approximately two

on new cases diagnosed in the U.S. alone every year. While the vast majority of BCCs sought early and cured with surgery or radiation, a small proportion of turrors can

me advanced and penetrate deeper into surrounding lissues (locally advanced), which are difficult to treat. Approximately 20,000 U.S. patients have advanced BCC and it is

ated that about 3,000 die each year. BCC marks the second non-melanoma skin

in advanced cutaneous squamous cell carcinoma (CSCC) in 2018.

r for which Libbayo has demonstrated first-in-class data and follows the initial U.S.

trial, the objective response rate (ORR) for patients (n+84) with locally advanced

are was 29% (95% CI: 19%-40%), with an estimated duration of response (DOR) eeting one year in 85% of responders. The durable disease control rate (DCR -

proc or stable disease lasting at least 6 months) was 60% (95% CI: 48%-70%). In a ninary analysis of patients (n=28) with metastatic disease, the ORR was 21% (95%

%-41%), with an estimated DOR exceeding one year in 83% of responders. The le DCR was 46% (95% CI: 28%-66%). All data were assessed by an independent.

ral review. Data are expected to continue to evolve with further follow-up across hold

their response for at least one year Sanofi and Regeneron plan regulatory submissions in 2020

durable responses in second-line advanced basal cell

asal cell carcinoma (BCC)

with metastatic BCC

et proups.

Pivotal Trial

March 2, 2020: Sarclisa® FDA Approval

> FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma

 Garcias is combination with pomalidamide and dearamithances (prodata) significantly advanced for nice (classes programation or earb by 60% compared to pom-data states in a plenatil tell (DA4)MMI to evaluate an ext-CO28 in combination with pom-data trait has present results to date.
 Marijo myeloma is the association to US3, approximative 32,5200 more than 153,5000 patients in the US3, approximative 32,5200

more that 130,000 pasens in the U.S.; approximately 32,000 Americans are diagnosed with multiple myelioma each year

PARIS – March 2, 2020 – The U.S. Food and Dirig Administration (FDA) has appreced Banclair⁶ (saturationab-inf) in combination with pomalifornide and desameritatione (pomdica) for the transmitter of adults with nispose frefanctory multiple mydores (RRMM), who have needwod at least beep pinc thatspice including lenationnide and a postauome imberts Sercise as expected to be available to potentiar the U.S. Indfig.

Serclise is a monoclonal antibody that binds to the CD38 receptor on multiple myeloma cells.

Today's FAA approval of Sarahas provides a rese hearment option for poletisk with difficult-form taplies reprinters. These are pattern students have numed to tencern resident to that proc reserve that is see Pail-Indono, Oniel Beachter Officer, Beach IV. Saraha, wai en found of ordering and diverging moticities that may change the prostice of moticities, and Sarahas officer a potential new stacked of come in the Unlet Salase. Ver contraw to revalues Sorahe is a comprehensive clinicity program for hotpitting, as well as in other blocd concerners and cold human.

Sarclisa Safety Profile and Efficacy in Difficult-to-Treat Patients

In the ICARIA-MM study, Sarelsa added to pom-tes (Sarcha combination tersory) domontanto a adatostado sprintaria impovement in programa (IPRS) with a median IPRS of 1133 months compared to 447 months with pom-tes alone (IPR) 5066; 895; C. 104.403; B. pol 0010; Sarchia combination thering also domontatista a significantly greater overall response rate compared to pom-des alone (IDA% vs. 35.3%, pv6.0001).

April 27, 2020: Libtayo[®] NSCLC 1624 Early Stop

Phase 3 Trial of Libtayo® (cemiplimab) as monotherapy for firstline advanced non-small cell lung cancer stopped early due to highly significant improvement in overall survival

Libitayo decreased the risk of death by 32.4% compared to chemotherapy
 Sanoti and Recension plan regulatory submissions in 2020

Paris and Tarrytown, N.Y. - April 27, 2020 – Sanot and <u>Reservors Planmaceuticals, inc.</u> MASDAD REGNI today emonanced the primary endpoint of overall survival (DS) ass me in a Parea 3 that company in particular Lubayo⁶ comprised by plasmo double chemolitenays is safetta with file file locally advanced or installation care-mail cell survival CRSCL) plat tested points for PD-11 m 2014 of survival CRS and a necessmication the instanced Data Monitoring Committee is stop for test early, the trial will be modified to also all plates the served. Libayo for file investigational accounted for the safet of the safet

The data will form the basis of regulatory submissions in the U.S. and European Union (EU) in 2020.

While demonstrating a survival benefit in find-line NSCLC has been challenging for immunoherapsia, the ours (FDA apposed and FD-I mountherapy has changed the therapeutic paradigm," said George D. Yanoposiok, M.D. PhD, Co-Founder, Presider and Chief Solieffit Officer of Respersence. We are plassed with the results of this faid that demonstrate the survival benefit of Labayo in these patients and hope it may become a potential demonstrate for physiciana and patients."

A potocol-sponford interim analysis conducted by the DMC demonstrated that plasmits haveds with Libben nonobraneys had a sponfinant increase in 0.5. Libbes doctmosted her ink of death by 12.64 (HH=0.0776; cl) 5.252-0.077, p=0.022, compared to platitum doublet chernofhrapy platiest being abet to crossover to Libbys of their disease progressed. No even Libbys eather spiral was identified. Deated to that shall be presented at a Libbe presented are libble and platiest being abet to crossover to Libbys of their disease progressed. No even Libbys eather spiral was identified. Deated that data will be present at at Libbe medical merity.

This is the largest clinical trial evaluating a PD-1 inhibitor as a first-line monotherapy in patients with advanced non-small cell lung cancer with high PD-11 expression. The positive results are extremely encouraging, and we look forward to advancing a potential terrative for the second second second block the Do-10 KBN Clinical Mont All. May 12, 2020: Sarclisa[®] IKEMA Early Achievement of Primary Endpoint

> Sarclisa[®] (isatuximab) Phase 3 IKEMA trial meets primary endpoint early in patients with relapsed multiple myeloma

- IKEMA trial results released early based on recommendation of an Independent Data Monitoring Committee
- Addition of Sarclisa significantly reduced the risk of disease progression or death compared to carfilzomib and dexamethasone

 Results will be submitted to an upcoming medical meeting and form the basis for regulatory submissions later this year

RIS - May 12, 2020 - The Phase 3 IKEMA clinical trial evaluating Sarcisal

Into – may Liz 2020 - The Place 3 inclusive certical and evaluating actual historicab) added to carfizerab and documenthatore melt be primary added and need interim analysis, demonstrating significantly prolonged progression-free survival repared to standard of care carfizorab and dexamethasone alone in patients with speed multiple myeloma. There were no new safety signals identified in this study.

When Service area solded to advanted-chare featment culticants and desamethascen in the phase 3 bid measure lawly demonstrated a significant modulion in risk of classes progression or cleaft, suis Junn Reis, N.D., Pho. Jucobi Heisd of Revents and Devisionen at Saruf. This is its second pacifier phase 3 bid for Sarolia, further supporting the potential our modulen has to improve outcomes for palents strugging with melapoid multiple myeloma.⁴ Kee 11 be submitted on upcoming module meling and are anticipated to form the second second second medianes and participates to form the second second second medianes and second median and second second bases.

out the Trial

randomized, multi-center, open label Phase 3 IKEMA clinical trial enrolled 302 ents with relapsed multiple myeloma across 69 centers spanning 16 countries. All sy participants received one to three prior anti-myeloma therapies. During the trial, disa was administered through an intravenous intois on at does of 10moka once

sis of regulatory submissions planned for later this year.

June 2, 2020: Sarclisa[®] IKEMA EHA Late Breaker

Sarclisa® EU Approval

June 2. 2020:

European Commission approves Sarclisa® (isatuximab) for adults with relapsed and refractory multiple myeloma

Sarclisa® (isatuximab) combination therapy demonstrated superior progression free survival and clinically meaningful depth of response in patients with relapsed multiple myeloma

Sarcisa added to carticomia and dexamethasone (Sarcisa combination relocated risk of disease progression or death by 47% versus standard of care carticomia and dexamethasone (Kd) alone Sarcisa combination therapy delivered considerable depth of response, with undetectable levels of multiple myetiona (MM) in early 70% of patients with nebased MM (MM) Choogadive UT⁶ semitherity) Results from first planned interim analysis of the Phase 3 INCMA fittal selected as stall-schaling presentation at PhAse 5 Yinta Compress

§5 – June 2, 2020 – Sarcias¹¹ (isatuxima): added to carticcemb and dexamethasone diac combiation therapy) reduced the risk of disease progression or dealth y 47% and ratio 0.531, 99% CI 0.316.839, p=0.007, n=739; compared to standard of care bombia and dexamethasone (74a) ratio strategied multiple myeloma Sarcias combination therapy compared to K\$1 alone showed a treatment benefit atent across multiple subgroups.

e results from the Phase 3 IKEMA trial follow the topline announcement on May 12, that Sarclisa combination therapy met the trial primary endpoint at the pre-planned manalysis. Interim results will be presented during the late-breaking session of the pean Hennatology Association (EHA) Virtual Congress (EHA25) on June 14, 2020 will form the basis for global regulatory submissions later this year.

In the Phase 3 I/CEMA trial, the addition of Sarctise to cartificante and disamethranon reduced the risk of disease progression of death by 41 percent compared to treatment with cartificante and disamethranon alone "sald Philippe Moreau, MD, Department of Hematology, University Honghai of Names, France. "These results suggest the potential of Sarctise to become a new standard of care in the relaxed multiple myediona satting."

n median progression free survival (PFS), defined as time to disease progression or to for Kd was 19 15 months, the median PFS for patients receiving Sarcias admittion therapy had not been reached at the time of the pro-planned interim analysis, tably and bierability of Sarcias observed in this that was consistent with the rever safety prefice of Sarcias in other cinical thata, with no new safety signals EC approval based on data from first randomized Phase3 trial (CARIA-MM) to report results evaluating an anti-CD38 monocional attibudy combined with porn-iden significantly reduced the risk of litogression of data by 40% versus power des alone Multiple myeloma is the second most common blood cancer, with payroximately 40,00 new cases per ver in Europe

June 2, 2020 — The European Commission (EC) has approved Sardisa¹⁰ b) in combination with pomalidomide and dexamethasone (pom-dex) for the of adult patients with relapsed and refractory multiple myeloma (MM) who have I least two prior therapies including lenalidomide and a proteasome inhibitor iemonstrated disease progression on the last therapy.

a monoclonal antibody (mAb) that binds to a specific epitope on the CD38 MM cells.

E C approval of Sarclisa represents an important additional therapeutic option impay set a new standard of care for reyrotom patients in Europe who are in d of new effective treatments because their dasease has returned or they have game refractory to their previous treatment', said John Read, MD, PhO, bal Head of Research and Development at Sandh. "Sarclisa in combination with risked cemonstrated mediain progression-fee survival of new / one year. A finth improvement over pom-dex alone, in patients who had already failed at least givor therapies."

acy and Safety Profile in Difficult-to-Treat Patients

as 31 CARL-MM study. Sarclisa added to pom-dex (Sarclisa combination 151) demonstrated a statistically alignizani improvement of progression-free FSU, with a median PFS of 1135 months compared to 6.47 months with pom-(mis51) (HR 0.566) SSC 10.44.4.81, pro-0013) sarclisa combination therapy instrated a significantly greater overall response rate compared to pom-dex (% vs. 353)%, pc0001). In additional analyses, Sarclisa combination therapy (to pom-dex alone showed a treatment benefit consistent across select reflective of rasi-work parkets with bytical yaters with bytic his dyogenetics.

SANOFI 🎝 BCC: Basal Cell Carcinoma; NSCLC: Non-Small Cell Lung Cancer; EHA: European Hematology Association



Sanofi in Oncology

John Reed

Executive Vice President, Global Head of Research & Development



Strengthening our organization with world-class talents





Yong-Jun Liu **Global Research** Head

Founder of MDACC

Cancer Immunology

Research Institute.

Research Head at

Medimmune

Alexander Zehnder **Global Franchise**

Former Head of Avastin franchise at Roche/Genentech, Head of Sanofi Italy

Head, Oncology



Nahid Latif

Oncology **Regulatory Head**

Former Executive Director, Oncology Regulatory Affairs at Merck & Co, Sr. Director Regulatory Affairs at AbbVie

Former Global Clinical Development Head, Hematology/Oncology, at Roche/Genentech

Dietmar Berger

Global

Development Head



Peter Adamson **Global Oncology Development Head**

Member of U.S. National Cancer Advisory Board, former Chair of Children's Oncology Group

Started in 2016


Started in 2018

Started in 2018


Started in 2019

Started in 2020

Sanofi platforms for Oncology drug discovery



Step #1: Lay a foundation with anchor assets in 4 oncology disease indications




MM: multiple myeloma; IO: Immuno-Oncology; CT: Chemotherapy; CSCC: Cutaneous Squamous Cell Carcinoma; BCC: Basal Cell Carcinoma; NSCLC: Non-Small Cell Lung Cancer; HR+: Hormone Receptor positive; SoC: Standard of Care

SANOFI

(1) 5-year prevalence, worldwide, 2018. Source: International agency for research on cancer (2) Surveillance, Epidemiology, and End Results (SEER) Program (3) Prevalence of ~1M for melanoma, ~5M for non-melanoma

Step #2: Build on the foundational assets with potential best-in-disease combinations



Sanofi Oncology portfolio: selected studies

SANOFI 🗸

		PoP PoC
Asset	Mechanism of Action	First in Human Post Proof of Principle trial Pivotal study
Sarclisa®	Anti-CD38 mAb	ICARIA: multiple myeloma – 3L+ RRMM
		IKEMA: multiple myeloma – 2L+ RMM
		GMMG - multiple myeloma - 1L NDMM Te - Induction & Maintenance
		IMROZ - multiple myeloma - 1L NDMM Ti
		ITHACA - Smoldering multiple myeloma - High-Risk
		Acute Myelogenous Leukemia/Acute Lymphoblastic Leukemia (T&B) - 1-2L Monotherapy
		SC administration
Libtayo ^{®(1)}	Anti-PD-1	2L BCC - locally advanced
		2L BCC - metastatic
		1L NSCLC - monotherapy
		1L NSCLC - chemotherapy combo
		2L Cervical Cancer
		CSCC Adjuvant
		CSCC Neo-Adjuvant ⁽²⁾
Anti-CEACAM5 '701	Maytansin loaded anti-CEACAM5 mAb	CARMEN-LC03 - NSCLC - monotherapy 2/3L
		CARMEN-LC04 - NSCLC - ramucirumab combination 2/3L
		CARMEN-LC05 - NSCLC - pembrolizumab combination 1L
		mBC & Pancreatic cancer - basket study
SERD '859	SERD	AMEERA-3 - HR+ mBC 2/3L monotherapy
		AMEERA-1 - CDK4/6i and Pi3Ki combos
		AMEERA-5 - 1L HR+ mBC combo with CDK4/6
		AMEERA-4 - Early HR+ BC
SAR439459	TGFb inhibition mAb	Advanced Solid Tumors (monotherapy & combo)
SAR440234	T-cell engaging bispecific (CD3/CD123) Ab	Leukemia
SAR441000	Cytokine mRNA ⁽¹⁾	Solid Tumors (monotherapy & combo)
SAR442257	Anti-CD3/CD28/CD38 Trispecific mAb	Multiple myeloma Study completed or primary endpoint achieved
SAR442085	Anti-CD38 mAB Fc engineered	Multiple myeloma Study in progress
SAR442720	SHP2 inhibitor ⁽¹⁾	Solid Tumors (monotherapy & combo) Study planned
SAR444245/THOR707	Not-alpha IL-2	Solid Tumors (monotherapy & combo)

PoP: Proof of Principle, early clinical evidence; PoC: Proof of Concept, clinical and commercial evidence to initiate pivotal study; BC: breast cancer; RRMM: Relapsed/Refractory multiple myeloma; NDMM: Newly Diagnosed multiple myeloma; SC: Sub-cutaneous; CSCC: Squamous cell skin cancer; BCC: Basal Cell Carcinoma; NSCLC: Non-small-cell lung carcinoma; mBC: metastatic Breast cancer; HR+: hormone receptor positive; CDK: cyclin-dependent kinases; Pi3Ki: phosphoinositide 3-kinase inhibitor. Other than the approved Sarclisa[®] + Pd indications listed on slide 6 in certain countries, these uses of isatuximab, including any SC use of isatuximab, are investigational and have not been evaluated by any regulatory authority (1) In collaboration with external partners (2) Pilot study – Non registration



Sarclisa® Ambition: Best-in-class profile in multiple myeloma

Dietmar Berger

Senior Vice President, Global Head of Development, Chief Medical Officer



Sarclisa®: Emerging best-in-class profile

Compelling profile in refractory MM

- Impressive PFS in 3L+ (ICARIA)
- Strong risk reduction of progression in 2L+ (IKEMA) with potent Kd backbone and against strong competitive data set⁽¹⁾

Aiming for best-in-class efficacy in 1L setting⁽²⁾

- Targeting deep responses in newly diagnosed MM
- Competitive timelines for 1L studies on VRd/KRd backbones

Aiming for leadership position in MM

3


- Next-generation assets
- Novel combinations
- Innovative subcutaneous approach⁽³⁾

PFS: Progression-Free Survival; MM: multiple myeloma; Kd: carfilzomib and dexamethasone; VRd: bortezomib, lenalidomide and dexamethasone; KRd: carfilzomib, lenalidomide and dexamethasone



(1) Use of isatuximab with Kd is investigational and has not been evaluated by any regulatory authority; no cross trial comparisons of efficacy should be made; statement expresses Sanofi's expectation that if approved for use in combination with Kd, Sarclisa will be competitive in the market. (2) Uses of isatuximab 1L is investigational and has not been evaluated by any regulatory authority (3) Subcutaneous use of isatuximab is investigational and has not been evaluated by any regulated by any regulatory authority

Sarclisa®: Anti-CD38 mAb with differentiated profile⁽¹⁾




Sarclisa[®] targets a different epitope than daratumumab and has demonstrated **multiple mechanisms of actions**^(1,2,3)

- ADCC, CDC and ADCP
- Inhibition of CD38 ectoenzyme activity
- Immunomodulation
- Direct apoptosis

Preclinical data support differentiated profile


Significant inhibition of CD38 ectoenzyme activity⁽¹⁾



CD38 thought to be dominant enzyme for the generation of adenosine (immuno-suppressive in bone marrow of MM patients)

Apoptotic activity in the absence of cross-linking^(2,3)

Caspase 3/7 activation in myeloma cells



Isatuximab directly inducing apoptosis of MM cells without requiring Fc-cross-linking agents Istatuximab inducing direct cytotoxicity against CD38+ myeloma cell lines in the absence of effector cells


AU, arbitrary units; (c)ADPR, (cyclic) adenosine diphosphoribose

SANOFI

mAb, monoclonal antibody; MM, multiple myeloma; MS, mass spectrometer; NAD nicotinamide adenine dinucleotide (1) Zhang B, et al. Presented at: AACR; April 5–9, 2014; San Diego, CA (2) Jiang H, et al. Leukemia. 2016;30:399–408 (3) Overdijk MB, et al. J Immunol. 2016;197:807–13 Note: the information on this slide is for the purpose of illustrating Sarclisa® s differentiated MOAs. No conclusions should be drawn regarding the clinical efficacy of Sarclisa® alone or in comparison to any other product. No head to head studies have been conducted comparing the clinical efficacy Sarclisa® with any of the products listed on this slide

Cytotoxicity in the absence of effector cells⁽²⁾

Cytotoxicity of myeloma cells



ICARIA displayed 11.5 months PFS for Sarclisa® in RRMM with at least 2 prior lines of treatment

	ICARIA		EQUULEUS ^(2,5)	ELOQUENT-3 ⁽³⁾	
	lsa-Pd	Pd	Dara-Pd	Elo-Pd	Pd
Design & patient characteristic					
Phase	3	3	1b	2	2
Patients in trial	N=154	N=153	N=103	N=60	N=57
Prior lines of therapy (Line: n%)	2-3: 66%; 4+: 34%	2-3: 66%; 4+: 34%	1-3: 48%; 4+: 52%	2-3: 60%; 4+:40%	2-3: 63%; 4+:37%
Efficacy ⁽¹⁾					
Median PFS, mo (95% CI)	11.5 (8.9-13.9)	6.5 (3.6-4.7)	8.8 (4.6-15.4)	10.3 (5.6-NR)	4.7 (2.8-7.2)
Hazard Ratio (95% CI)	0.596 (0.436-0.814)		-	0.54 (0.34-0.86)	
Safety					
TEAE Gr 3-4	85%	71%	99%	57%	60%
Discontinuation Rate due to AEs	7%	9%	13% ⁽⁴⁾	18%	24%

RRMM: Relapsed/refractory multiple myeloma; Pd: pomalidomide and dexamethasone; PFS: Progression Free Survival; AE: Adverse event; TEAE: Treatment Emergent Adverse Event (1) Overall Response Rate: Isa-Pd (60.4%), Pd (35.3%), Dara-Pd (60%), Elo-Pd (53.3%) (2) Chari A, et al. Blood. 2017;130:974-981 (3) Dimopoulos MA, et al. N Engl J Med. 2018;379:1811–22 (4) U.S. Prescribing Information (5) EQUULEUS was a single arm study. The primary endpoint was safety. ORR and MRD were secondary endpoints. The PFS of daratumumab has been studied in phase 3 trials with other backbone combinations.

SANOFI 🎝

Note: No head to head studies have been conducted comparing the safety or efficacy of Sarclisa® with daratumumab or elotuzumab. The information on this slide is for the purpose of illustrating Sanofi's expectation that Sarclisa® will be competitive in the market. The studies listed on this slide involve different study designs, endpoints and patient populations, and no inferences of clinical superiority should be made.

IKEMA met primary endpoint early

•	Ν	=	302
---	---	---	-----

- Isa-Kd: N=179 Median age 65 (37–86)
- Kd: N=123 Median age 63 (33-90)
- Number of prior lines:
 - 1: 44% Isa-Kd; 45% Kd
 - 2+: 56% Isa-Kd; 55% Kd

Results		lsa-Kd	Kd
	PFS HR	0.53 (0.32-0.89	9, p=0.0007)
	mPFS	Not reached	19.15m
	ORR	87%	83%
Efficacy	≥VGPR	73%	56%
	≥CR	40%	28%
	MRD-Neg (10 ⁻⁵ , ITT)	30%	13%
	Median exposure	80w	61w
Safety	Grade ≥3 TEAEs	77%	67%
profile ⁽¹⁾	Fatal TEAEs	3%	3%
	Discont. due to TEAEs	9%	14%

Full results to be presented at EHA

ITT: intention-to-treat; Kd: carfilzomib and dexamethasone; HR: Hazard Ratio; PFS: Progression Free Survival; TEAE: Treatment Emergent Adverse Event; ORR: Overall Response Rate; CR:



Complete Response; VGPR: Very good partial response (1) Median duration of follow up: 20.7 months

Note: Use of isatuximab with Kd is investigational and has not been evaluated by any regulatory authority.

Reminder of CANDOR⁽¹⁾ results

Patient characteristics	Results		Dara-Kd	Kd
		PFS HR	0.63 (0.45-0.86	5, p=0.0014)
	Efficacy	mPFS	Not reached	15,8m
 N = 466 Dara-Kd: N=312 Median age 64 (29–84) Kd: N=154 Median age 65 (35-84) 		ORR	84%	75%
		≥ VGPR	69%	49%
		≥CR	29%	10%
		MRD-Neg (10 ⁻⁵ , ITT)	18%	4%
 Number of prior lines: 	Safety profile ⁽²⁾	Median exposure	68w	40w
1: 46%2+: 54%		Grade ≥3 TEAEs	82%	74%
		Fatal TEAEs	10%	5%
		Discont. due to TEAEs	22%	25%

Dara: daratumumab; ITT: intention-to-treat; Kd: carfilzomib and dexamethasone; HR: Hazard Ratio; PFS: Progression Free Survival; TEAE:Treatment Emergent Adverse Event; ORR: Overall Response Rate; CR: Complete Response; VGPR: Very good partial response


(1) CANDOR (NCT03158688) is a randomized phase III study comparing the combination of daratumumab + Kd to Kd alone in patients with RRMM

(2) Median duration of follow up: 17.1m-17.2 months

SANOFI 🌍

Note: no head to head studies have been conducted comparing the safety and efficacy of Sarclisa[®] plus Kd against daratumumab plus Kd. The information on this slide is for the purpose of illustrating Sanofi's expectation that Sarclisa[®] will be competitive in the market if approved for use with Kd. CANDOR and IKEMA involve different study designs and patient populations, and no implications of clinical superiority should be made from this slide period.

Sarclisa[®] in newly diagnosed MM: early promising results for Isa-KRd and Isa-VCd/VRd quadruplets



ORR: Overall Response Rate; MRD: Minimal Residual Disease, at sensitivity level of 10⁻⁵; VGPR: Very good partial response; VRd: bortezomib, lenalidomide and dexamethasone; KRd: carfilzomib, lenalidomide and dexamethasone; VCd: bortezomib, cyclophosphamide, and dexamethasone



(1) ASCO abstract number 8508 (2) Defined as ISS stage 2 or 3 and [Del (17p) or t(4;14) or t(14;16) or > 3 copies 1q21] (3) ASCO abstract number 8529 (4) Results of 15 efficacy-evaluable patients (5) Results of 26 efficacy-evaluable patients (6) MRD evaluable (7) Intention-to-treat analysis. Note: use of isatuximab in these studies are investigational and has not been evaluated by any regulatory authority

Expanding Sarclisa[®] to early lines with competitive timelines

Study	Arm	Line	Study initiation	Headline res	
ICARIA	Isa-Pd vs. Pd	3L+	H2 2016	H1 2019	
IKEMA	lsa-Kd vs. Kd	2L+	H2 2017	H1 2020	
IMROZ	Isa-VRd vs. VRd	1L Ti	H2 2017	2022e	
GMMG	Isa-VRd vs. VRd	1L Te	H2 2018	2024e	Potential future SoC backbone
EMN	Isa-KRd vs. KRd	1L Te	H2 2020	-	Suchbolic
ITHACA	Isa-Rd vs Rd	High risk smoldering	Q2 2020	After 2024	


No CD38 VRd or KRd-based quadruplets approved for newly diagnosed multiple myeloma



Pd: pomalidomide and dexamethasone; Kd: carfilzomib and dexamethasone; VRd: bortezomib, lenalidomide and dexamethasone; KRd: carfilzomib, lenalidomide and dexamethasone; Rd: lenalidomide and dexamethasone; SoC: Standard of Care

Other than the approved Sarclisa[®] + Pd indications listed on slide 6 in certain countries, these uses of isatuximab, including any SC use of isatuximab, are investigational and have not been 22 evaluated by any regulatory authority

Sarclisa®: Attractive 2L+ opportunity with the ambition to compete in the significantly larger 1L setting



(1) Based on PFS

SANOFI S Other than the approved Sarclisa® + Pd indications listed on slide 6 in certain countries, these uses of isatuximab, including any SC use of isatuximab, are investigational and have not been evaluated by any regulatory authority Source: Decision Resources Group, 2019; Sanofi data

Sarclisa®: Building leadership position in multiple myeloma

Exploring novel combinations

- Bi-specifics
- TGFb
- THOR707




Next-generation assets

- Enhanced antibodydependent cellular cytotoxicity:
 Fc engineered anti CD38
- First-in-class tri-specific: Anti CD38-CD28-CD3

Subcutaneous patient-centric delivery⁽¹⁾

Sarclisa®: Summary

Ambition: Best-in-class profile



Differentiated Mechanism of Action

11.5m PFS in 3L+ patients (ICARIA)

Strong risk reduction of progression in 2L setting (47%), on top of Kd standard of care backbone (IKEMA)

Promising early results in newly diagnosed MM with gold standard of care (KRd, VRd, VCd); competitive timelines in 1L Ti & 1L Te in VRd combos; initiating phase 3 in high-risk smoldering multiple myeloma

Aspiring for leadership position in multiple myeloma with next generation molecules and novel combinations

PFS: Progression free survival; MRD: Minimal Residual Disease; VRd: bortezomib, lenalidomide and dexamethasone; Kd: carfilzomib dexamethasone, KRd: carfilzomib, lenalidomide and dexamethasone; VCd: bortezomib, cyclophosphamide, and dexamethasone; SoC: Standard of Care





Libtayo[®] Ambition: Serving larger patient populations with competitive profile

Alexander Zehnder

Global Franchise Head, Oncology



Libtayo[®]: Serving larger patient populations with competitive profile

Leadership in nonmelanoma skin cancer

- First-in-class in locally advanced or metastatic CSCC
- Positive data in locally advanced or metastatic BCC (2L post HHI)
- Expansion in adjuvant/neoadjuvant CSCC


2 Gain share in 1L NSCLC

- Competitive profile in monotherapy in patients with PD-L1 <u>></u>50%
- Data in chemotherapy combination in any PD-L1 status expected in 2021

Backbone for novel combinations

3

- Addressing the limitations of anti-PD(L)1 monotherapy
 - In-house and external combos focusing on NSCLC
 - Combos with Immuno-Oncology compounds & complementary molecules



Libtayo[®] to be first in 3 significant market segments in non-melanoma skin cancer


Locally advanced or metastatic CSCC

Launched in 2018 in U.S. and 2019 in Europe

~15,000 eligible patients(1)

OS at 24 months =73.3% (95% CI:66.1-79.2)⁽²⁾

Probability of survival (N=193)




Locally advanced or metastatic BCC (2L)

Positive data announced on May 5, 2020, expected launch in 2021

2,000-4,000 eligible patients⁽¹⁾

Meaningful and durable responses in 2L BCC⁽³⁾: ~85% of responses maintained for at least 1 year




Neo-/Adjuvant CSCC

Phase 3 results expected in 2024 + neoadjuvant in 2023⁽⁵⁾, expected launch in 2024

~60,000 eligible patients(1)

Pathologic response to Neo-adjuvant Libtayo^(4,5)



SANOFI 🎝 🖁

CSCC: cutaneous squamous cell carcinoma; BCC: basal cell carcinoma; OS: overall survival; la: locally advanced, m: metastatic; ORR: objective response rate (1) U.S., EU5 (2) Rischin ASCO 2020 (3) 2020 Sanofi press release May 5, 2020 (4) Gross et al., ESMO 2019 (5) Non-registrational study


Fast uptake in advanced CSCC secures market leadership in 2nd year post launch

Libtayo[®] share in advanced CSCC reached 47%

Claims increased 4-fold in since launch

Sales momentum

Libtayo® annualized sales of ~\$300m



Worldwide annualized sales of \$300m with room to grow in la/m CSCC



Significant commercial opportunity in 1L NSCLC


U.S. eligible patient population for initial lung cancer approval

1L mNSCLC

EGFR, -ROS)

Significant opportunity in largest PD(L)-1 indication


Worldwide PD(L)-1 sales in mNSCLC, \$bn, 2019



~120k Biomarker free (Non -ALK, -~80%

Eligible population for PD-L1 High approval	~17k
PD-L1 class share	~60%
PD-L1 high (<u>></u> 50%)	~30%

Competitive profile in PD-L1>50%, second Libtayo® 1L study (any PD-L1 status) to read out in 2021





1L NSCLC Libtayo plus chemotherapy, independent of PD-L1 expression, data expected in 2021



OS: Overall survival, PFS: Progression Free survival, QoL: Quality of life; CT: Chemotherapy; PBO: Placebo; Pt: Platinum; NSCLC: non-small cell lung cancer For illustrative purposes only. Not based on head to head data. Limited conclusions should be derived from this indirect comparison of efficacy given that the variability of trial designs (1) Overall ITT Analysis, Sanofi Press Release April 27 (2) Modified ITT: patients with ≥50% PD-L1 expression in tumor in whom PD-L1 assay was performed according to FDA-labeling (3) Mok et al., Lancet 2019 4) Reck et al., JCO 2020

Libtayo[®]: Potential backbone for novel combinations⁽¹⁾





Libtayo[®]: Summary

Ambition: Serving larger patient populations with competitive profile

Leadership in non-melanoma skin cancer, with opportunity to be first across locally advanced/metastatic CSCC & BCC and adjuvant CSCC

Competitive profile in 1L NSCLC in PD-L1 \geq 50%; data expected in 2021 in combination with CT for broad 1L population irrespective of PD-L1 status

Potential backbone for novel combinations to improve patient outcomes vs. current Immuno-Oncology regimens





Anti-CEACAM5 '701 Ambition: First-in-class CEACAM5targeting ADC

Peter Adamson

Global Oncology Development Head



Anti-CEACAM5 '701: First-in-class CEACAM5-targeted ADC

Standard of Care for CEACAM5+ NSCLC patients progressing on IO therapy

- PoC as single agent in 2L+
- Pivotal fast-to-market study initiated in 2L monotherapy
- PoC study in combination with ramucirumab initiated in 2L

Aiming to become cornerstone therapy in 1L PD-1 combination

- PoC in 1L combination with PD-1 to be initiated
- Pivotal study in combination with PD-1 to follow

Expand beyond lung cancer

3

- Exploring anti-CEACAM5 '701 in gastric cancer, breast cancer and pancreatic cancer
- Exploring delivery of complementary payloads with CEACAM5-antibody in further solid tumors

Anti-CEACAM5 '701 is a highly specific antibody designed to deliver payload specifically to tumor cell

Tumor selective profile

CEACAM5:

 Highly expressed on tumor cells, limited expression in healthy cells


Anti-CEACAM5 '701:

 Humanized antibody with high selectivity for CEACAM5

Payload:

- DM4/Maytansinoid
- Anti-tubulin, 100-times more potent than docetaxel


Linker stable in plasma



Anti-CEACAM5 '701 being developed for anti-tubulin sensitive tumors with high CEACAM5 expression

High prevalence in several cancer types

Cancer Type	Population with high CEACAM5 expression ⁽¹⁾	1L metastatic incidence (thousands, U.S.)	Anti-tubulin- sensitive
Gastric Adenocarcinoma	25-30%	12	Yes
NSCL Adenocarcinoma	20-30%	74	Yes
Pancreas adenocarcinoma	10-20%	27	Yes
Metastatic breast cancer	5-15%	39	Yes
Colorectal Adenocarcinoma	80-90%	44	No




CEACAM5 is expressed with significant frequency and intensity in several cancer types



IHC, immunohistochemistry; NSCL, non-small cell lung; Scc, squamous cell carcinoma; Srcc: signet ring cell carcinoma; Adca: adenocarcinoma
 (1) ≥2+ intensity in ≥ 50% of tumor cells by IHC
 Note: SAR408701 is an asset under investigation, not approved by regulators

First-in-human anti-CEACAM5 '701 phase 1/2 study design⁽¹⁾



Primary endpoints:

- Dose-limiting toxicity (DLT; escalation phase)
- Overall response rate (ORR; expansion phase)

Secondary endpoints:

- Safety
- Recommended Phase 2
 dose identification
- Duration of response (DOR)

MTD: Maximum Tolerated Dose, nsq: non-squamous; DLT: dose limiting toxicity

(1) A first-in-human study for the evaluation of the safety, PK and antitumor activity of anti-CEACAM5 '701 in patients with advanced solid tumors (NCT02187848)

(2) High Expressor NSCLC – 2 interim analyses (at first 15 treated patients and at first 30 treated patients)

(3) Small Cell Lung Cancer, Gastric and Colorectal

SANOFI

Note: SAR408701 is an asset under investigation, not approved by regulators

First-in-human anti-CEACAM5 '701 phase 1/2: baseline patient characteristics (nsq NSCLC cohorts)


Characteristic	High expressors (n = 64)	Moderate expressors (n = 28)	Total (n = 92)	
Age, years				
Median (range)	61.5 (41-91)	64.5 (31-73)	62.5 (31-91)	
Race, n (%)				
White	52 (81.3%)	25 (89.3%)	77 (83.7%)	
Asian	12 (18.8%)	3 (10.7%)	15 (16.3%)	
Sex, n (%)				
• Male	37 (57.8%)	10 (35.7%)	47 (51.1%)	
Female	27 (42.2%)	18 (64.3%)	45 (48.9%)	
ECOG PS, n (%)*				
• 0	19 (29.7%)	7 (25.0%)	26 (28.3%)	
• 1	45 (70.3%)	20 (71.4%)	65 (70.7%)	
Number of organs involved, n (%)				
• ≥3	38 (59.4%)	14 (50%)	52 (56.5%)	
Number of prior regimens for advanced disc	ease			
Median (range)	3.0 (1-10)	3.0 (1-7)	3.0 (1-10)	
Prior treatment, n (%)				
Anti-tubulin	39 (60.9%)	17 (60.7%)	56 (60.9%)	
Anti-PD-1/PD-L1	45 (70.3%)	24 (85.7%)	69 (75.0%)	

SANOFI 🌍


A total of 91 patients had adenocarcinoma; *One patient in the moderate expressor cohort had an ECOG PS of 3. Note: SAR408701 is an asset under investigation, not approved by regulators

Anti-CEACAM5 '701: Tumor size reduction & treatment duration in high expressors

Outcome & Duration of Treatment



Best Relative Tumor size reduction




Median Duration of Response was 5.6 months (range: 2.0 – 24.6 months)

SANOFI 🌍

Best relative tumor size reduction: Patients who had unconfirmed Partial Response (>30% decrease) were counted as Stable Disease for Best Overall Response Note: SAR408701 is an asset under investigation, not approved by regulators

Results support use of anti-CEACAM5 '701 in nsq NSCLC CEACAM5 high expressors

Overall Response Rate (%)



Anti-CEACAM5 '701: Favorable safety profile demonstrated to date

Pooled safety analysis, moderate & high expressors cohorts

	Anti-CEACAM5 '701 100 mg/m ² Q2W (n=92)		
	All Grades, n (%)	Grade ≥3, n (%)	
Any class, clinical treatment emergent adverse events ≥ 10%	92 (100%)	47 (51.1%)	
Corneal Adverse Events (incl. Keratopathy/Keratitis)	35 (38.0%)	10 (10.9%)	
 Of which leading to dose modification 	25 (27.2%)	7 (7.6%)	
Asthenia	34 (37.0%)	4 (4.3%)	
Peripheral neuropathy (SMQ ⁽¹⁾)	25 (27.2%)	1 (1.1%)	
Diarrhea	21 (22.8%)	1 (1.1%)	
Dyspnea	20 (21.7%)	10 (10.9%)	
Decreased appetite	19 (20.7%)	0	
Cough	14 (15 2%)	0	
Nausea		1 (1.1%)	
Arthralgia	10 (10.9%)	0	
Constipation	10 (10.9%)	0	
Hematological toxicity			
Neutropenia	4 (4.4%)	0	
Anemia	69 (75.8%)	2 (2.2%)	
Thrombocytopenia	11 (12.2%)	0	

Ocular events most frequent clinical adverse event, manageable with dose delay and/or dose reduction

Dyspnea most frequent serious adverse event, reported in 5 (5.4%) patients, all as a **symptom of progressive disease**

Much improved hematologic and GI toxicity profile compared to conventional therapy (docetaxel boxed warning for neutropenia and hepatic effects)

Potential strongly differentiating value proposition for target patients



(1) Standardized MedDRA Queries (SMQ): "peripheral neuropathy" (broad + narrow) Note: SAR408701 is an asset under investigation, not approved by regulators

Taking anti-CEACAM5 '701 across all lines of treatments in nsq NSCLC

Line of treatment	Ambition	Target population ⁽¹⁾	Study name	Regimen	Size	Primary endpoints	Initiation	Read-out
2L+	Become SoC for 2L+ patients who have 2L+ progressed following		CARMEN- LC03	Monotherapy	554	PFS and OS	Q1 2020	2022e
26+	immune oncology or chemotherapy	~10-15k	CARMEN- LC04	Combo with ramucirumab	30	ORR	Q2 2020	2021e
1L	Become cornerstone therapy in 1L PD-1 combination	~12-18k	CARMEN- LC05	Combo with PD-1	45	ORR	Q3 2020	2022e


Companion diagnostic (CDx) being developed to identify CEACAM5+ patients




PFS Progression Free Survival; ORR Overall Response Rate; DoR Duration of Response; PK: Pharmacokinetics; TTP: Time To Progression; QoL: Quality of Life; SoC: Standard of Care (1) Kantar CancerMPact® 2019, U.S., CEACAM5 high expressors & EFGR/ALK wild-type Note: SAR408701 is an asset under investigation, not approved by regulators

Anti-CEACAM5 '701: focused on a significant subpopulation in nsq NSCLC

Eligible patients in 2L+ nsq NSCLC (U.S.), in thousands




Eligible patients in 1L nsq NSCLC (U.S.), in thousands





 Nsq: non-squamous; wt: wild-type; TKI: Tyrosine Kinase Inhibitors; m: Mutant Source: Kantar CancerMPact[®] 2019 – U.S.
 Note: SAR408701 is an asset under investigation, not approved by regulators

Anti-CEACAM5 '701: Novel CEACAM5 ADCs with different payloads expands opportunity across many tumor types



Anti-CEACAM5 '701: Summary

Ambition: First-in-class CEACAM5-targeting ADC



Efficacy and favorable safety profile demonstrated in patients with CEACAM5 high expressing 2L+ nsq NSCLC

Aiming to offer new treatment options for patients with CEACAM5 high expressing nsq NSCLC across all lines (~25% of patients)

- SoC for patients progressing on Immuno-Oncology therapy
- Aiming to become cornerstone therapy with PD-1 inhibitor in 1L

Taking CEACAM5 Antibody Drug Conjugates beyond lung cancer

- Exploring anti-CEACAM5 '701 in gastric, breast and pancreatic cancer
- Exploring different payloads in multiple solid tumor types



SERD '859 Ambition: best-in-class endocrine backbone in HR+ BC

Peter Adamson

Global Oncology Development Head



SERD '859: Potential best-in-class endocrine backbone in HR+ breast cancer

Fast to market single agent in 2L+ mBC

- Fast recruiting due to the lack of cardiac monitoring
- Evaluating combination with Pi3Ki in 2L+

2 CDK4/6 combination in 1L mBC

- Expected excellent combinability with CDK4/6 due to lack of bone marrow suppression
- PoC expected in H2 2020 and phase 3 initiation before year-end

Expansion to Early breast cancer

3

- Window of opportunity study
- I-SPY collaboration



HR+: hormone-receptor positive; mBC: metastatic Breast Cancer; CDK: cyclin-dependent kinases; Pi3Ki: phosphoinositide 3-kinase inhibitor; PoC: Proof of Concept, clinical and commercial evidence to initiate pivotal study

SAR439859 is an asset under investigation, not approved by regulators

SERD '859 target profile provides potential to become the new standard endocrine backbone for HR+ breast cancer

SERD '859 target profile



Efficacy: potent broad ER degrader irrespective of ESR1 mutation status

Safety: no cardiotoxicity, no liver toxicity signals to date




SANOFI

Tolerability: no grade 3 event, good GI profile, QoL and no vision impact

Combinability: Clean hematological toxicity profile

Treatment burden: Oral



Evolution of SoC in HR+ breast cancer

HR+: hormone-receptor positive; ER: Estrogen Receptor; ESR1: Estrogen Receptor 1; QoL: Quality of life; GI: Gastrointestinal; DDI: drug interaction, CT: chemotherapy; Tam: tamoxifen; AI: aromatase inhibitor; F: fulvestrant; CDK: cyclin-dependent kinases; QTc: QT corrected; Pi3Ki: phosphoinositide 3-kinase inhibitor; mTORi: mammalian target of rapamycin inhibitors; SoC: Standard of Care

(1) Some patients only receive endocrine therapy, depending on disease staging SAR439859 is an asset under investigation, not approved by regulators

AMEERA-1 design: Single-Agent and Combinations

Part B (QD): Expansion phase – Single agent
 400mg QD – N = 78 (62 patients treated)

Part A: Dose escalation phase Single agent⁽¹⁾ **Part B (BID):** Expansion phase – Single agent 400mg BID - N = 56


Part C: Dose escalation phase – Combination⁽²⁾ Part D: Expansion phase – Combination, RD (part C) + CDK4/6 – N = 28

30 among the 62 treated patients (48.4%) had \geq 3 prior lines of therapy in the advanced setting



Note: Doses explored (mg): Daily: 20, 100, 200, 400, 600; Twice daily: 2*200, 2*300; RD: recommended dose (1) Based on occurrence of dose liming toxicity at cycle 1, (N=31-42 patients) together with target saturation (FES PET scans) and pharmacokinetics parameters (2) Based on occurrence of dose liming toxicity at cycle1 (N=12 patients) and pharmacokinetics parameters, up to 2 recommended doses can be selected SAR439859 is an asset under investigation. not approved by regulators

SERD '859: Clinically meaningful treatment effect in heavily pre-treated population





ESR1: Estrogen Receptor 1; CDK: cyclin-dependent kinases; QTc: QT corrected; mTORi: mammalian target of rapamycin inhibitors SAR439859 is an asset under investigation, not approved by regulators

Backbone landscape in 2L+ setting

	Trial	Study regimen	N	SERD '859 / Fulvestrant alone results		Prior CDK4/6, mTOR, Fulvestrant
		indi otday reginen		ORR	CBR	
	AMEERA-1	SERD '859	59	6.8%	35.6%	Permitted
	AMEERA-1	SERD '859	14 ⁽¹⁾	21.4%	64.3%	No
	SANDPIPER	Fulvestrant (+/- taselisib)	134	11.9%	37.3%	No
	PALOMA-3	Fulvestrant (+/- palbociclib)	138	11%	36%	No
	SoFEA	Fulvestrant (+/- anastrozole)	178	8%	31%	No
-	EFFECT	Fulvestrant (+/- exemestane)	270	7.4%	32.2%	No

ORR: objective response rate; CBR: clinical benefit rate; CDK: cyclin-dependent kinases; mTORi: mammalian target of rapamycin inhibitor Source: data on file

SAR439859 is an asset under investigation, not approved by regulators

(1) subpopulation appropriate to compare directly to fulvestrant literature and relevant to performance in earlier lines

Clean safety profile will be required to become backbone

SERD '859 ≥150 mg QD⁽¹⁾ – All patients (N=62)

TRAEs, n(%)	Grade 1-2	Grade ≥ 3
Any class	38 (61.3)	-
Hot flush	10 (16.1)	-
Constipation	6 (9.7)	-
Arthralgia	6 (9.7)	-
Decreased appetite	5 (8.1)	-
Vomiting	5 (8.1)	-
Diarrhea	5 (8.1)	-
Nausea	5 (8.1)	-
Fatigue	4 (6.5)	-


Other SERD development programs

GDC9545⁽²⁾ - 40 patients in cohort A (monotherapy)

- **3 Grade 3 events:** fatigue, transaminase increase, diarrhea
- 3 patients (7,5%) with asymptomatic bradycardia (all grade 1)

AZD9833⁽³⁾ - 60 patients

- **3 Grade 3 events:** visual disturbance, dizziness, vomiting
- 45% sinus bradycardia, including 2 patients with grade 2



SANOFI

 Degrader chain
 Image: Classical structure


 Scaffold
 Image: Classical structure

TRAE: Treatment-related adverse event


(1) Campone, et. Al, ASCO 2020 (2) ASCO Poster #108, Lim et al. ASCO 2020 (3) ASCO Poster #109, Hamilton et al. ASCO 2020 SAR439859 is an asset under investigation, not approved by regulators

SERD '859: No significant bone marrow suppression observed, supporting combinability potential

3-months repeat-dose Toxicity Study in Rats



Ambition to establish SERD '859 as best-in-class endocrine backbone in HR+ breast cancer



2L/3L mBC expected to reach market in 2022, >1 year ahead of other SERDs in development



HR+: hormone-receptor positive; BC: breast cancer; CDK: cyclin-dependent kinases; Pi3Ki: phosphoinositide 3-kinase inhibitor
 (1) Non-registrational study
 SAR439859 is an asset under investigation, not approved by regulators


SERD '859: Announcing the I-SPY 2 Endocrine Optimization Protocol (EOP) pilot study to establish new platform

 \bigcirc

MRI

For patients with high risk early stage breast cancer who may not benefit from neoadjuvant chemotherapy

- Feasibility endpoint
- Informative MRIs & biomarkers
- Position SERD '859 to become the endocrine backbone for future I-SPY 2 adaptive neoadjuvant combinations



SERD '859 data supports ambition to become BiC endocrine backbone in HR+ BC across treatment lines

	Target profile	SERD '859 phase 1 data
Efficacy	100% receptor degradation: potent broad ER degrader irrespective of ESR1 mutation status	Competitive ORR and CBR
Safety	No cardiotoxicity No liver toxicity	No bradycardia signals No QTc prolongation signals No liver enzyme elevation signals
Tolerability	Favorable GI profile Favorable Quality of Life No vision impact	No grade 3 TRAEs, incl. nausea, vomiting, dizziness No visual disturbances signals
Combinability	Benign hematologic toxicity profile	Clean hematological profile with no significant myelosuppression



HR+: hormone-receptor positive; BC: breast cancer; ER: Estrogen receptor; ESR: Estrogen Receptor 1; ORR: objective response rate; CBR: clinical benefit rate; TRAE: Treatment-related adverse event; GI: Gastrointestinal SAR439859 is an asset under investigation, not approved by regulators

SERD '859: Summary

Ambition: Best-in-class endocrine backbone in HR+ breast cancer



Compelling efficacy with CBR of 36% (all-comers) and 64% (in patients without prior SERD, mTORi, CDK4/6)

Demonstrated safety and tolerability required to become best-in-class backbone

Aiming for initial approval in 2022, >1 year before other SERDs in development

Lack of bone marrow suppression should result in excellent combinability

HR+: hormone-receptor positive; CBR: Clinical Benefit Rate; CDK: cyclin-dependent kinases; Pi3Ki: phosphoinositide 3-kinase inhibitor; mTORi: mammalian target of rapamycin inhibitors SAR439859 is an asset under investigation, not approved by regulators



Conclusions

John Reed

Executive Vice President, Global Head of Research & Development



Ambition to shape 4 anchor assets into blockbusters


	Ambition	Current status	Blockbuster potential
Sarclisa®(1)	Best-in-class profile in multiple myeloma	Approved with Pd for RRMM ⁽³⁾	Positive pivotal data with Kd in 2L+ RMM P3 (IKEMA) P3 in 1L Ti/Te MM ongoing SMM to be initiated ⁽⁴⁾
Libtayo ^{®(2)}	Serving larger patient populations with competitive profile	Approved in metastatic/locally advanced CSCC	Positive pivotal data in in 1L NSCLC Positive pivotal data in 2L BCC Adjuvant CSCC P3 ongoing Backbone for novel combinations
Anti-CEACAM5 '701 ^(1,5)	First-in-class CEACAM5-targeting ADC for lung cancer	PoC data in CEACAM5+ 2L nsq NSCLC (single agent)	Pivotal P3 (fast-to-market) 2L CEACAM5+ NSCLC ongoing, PoC in earlier NSCLC lines and further CEACAM5+ tumors initiating
SERD '859(1,5) Priority asset	Best-in-class endocrine backbone for HR+ breast cancer	PoC data in 3L+ HR+ BC (single agent)	Pivotal P2b (fast-to-market) in 2L+ HR+ BC PoC combo and studies in earlier lines ongoing

MM: multiple myeloma: RRMM: Relapsed/refractory multiple myeloma; TI: Transplant ineligible; Te: Transplant eligible; HR+: Hormone Receptor positive; CSCC: Cutaneous Squamous Cell Carcinoma: BCC: Basal Cell Carcinoma; NSCLC: Non-Small Cell Lung Cancer; SMM: Smoldering multiple myeloma; ADC: Antibody Drug Conjugate; BC: breast cancer; nsg: non-squamous; PoC: Proof of Concept, clinical and commercial evidence to initiate pivotal study

SANOFI 🎝

(1) Wholly owned assets (2) Libtayo® in collaboration with Regeneron - Sales are consolidated by Regeneron in the U.S. (3) and ≥2 prior therapies, including lenalidomide and a proteasome inhibitor. Approved in the U.S., EU, Canada, Australia and Switzerland, indication in certain non-U.S. countries also includes disease progression on last therapy (4) These uses of 60 isatuximab are investigational and have not been evaluated by any regulatory authority. (5) Anti-CEACAM5 '701 and SERD '859 not approved by the regulators

Significant news flow expected in the next 18 months





PoP: Proof of Principle, early clinical evidence; PoC: Proof of Concept, clinical and commercial evidence to initiate pivotal study; OS: Overall Survival; BC: breast cancer; RRMM: Relapsed/Refractory multiple myeloma; Ti: Transplant ineligible; Te: Transplant eligible; SC: Sub-cutaneous; BCC: Basal Cell Carcinoma; NSCLC: Non-small-cell lung carcinoma; NDMM: Newly Diagnosed multiple myeloma; MM: Malignant Melanoma; CRC: Colorectal cancer; MuC: Metastatic Urothelial Carcinoma; AML: Acute myeloid leukemia; PTCL: Peripheral T-Cell Lymphoma; CT: chemotherapy (1) In collaboration (2) Malignant Melanoma

Our ambition in Oncology



Transform strong science into commercial leadership



Focus on 4 core areas with ambition to shape 4 anchor assets into blockbusters



Develop novel combinations to improve patients' outcomes



Position Sanofi as partner of choice in selected areas based on best-in-class backbones and leading platforms to generate first-in-class medicines

Q&A session



Paul Hudson Chief Executive Officer



John Reed

Executive Vice President, Global Head of Research & Development



Bill Sibold Executive Vice President, Sanofi Genzyme



Dietmar Berger Senior Vice President, Global Head of Development, Chief Medical Officer



Peter Adamson Global Oncology Development Head



Laurent Debussche Global Molecular Oncology Research Head



Dmitri Wiederschain Global Immuno-Oncology Research Head



Alexander Zehnder Global Franchise Head, Oncology

